Improved outcome of hematopoietic SCT in patients with homozygous gene variant of Toll-like receptor 9

Bone Marrow Transplantation

Volumn 44, Issue 5, 2009, Pages 295-302

  Elmaagacli, A H ^a   Koldehoff, M ^a   Beelen, D W ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 9;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; DONOR SELECTION; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; SEPSIS; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; UPREGULATION; WILD TYPE;

ADOLESCENT; ADULT; AGED; ALLELES; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; COHORT STUDIES; CPG ISLANDS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TOLL-LIKE RECEPTOR 9; TREATMENT OUTCOME; UP-REGULATION; YOUNG ADULT;

EID: 70349115053     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.32     Document Type: Article

References (31)

1. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001; 1: 135-145 (review).
2. Medzhitov R, Janeway Jr C. The Toll receptor family and microbial recognition. Trends Microbiol 2000; 8: 452-456.
3. Chiffoleau E, Heslan J-M, Heslan M, Louvet C, Condamine T, Cuturi M-C. TLR9 ligand enhances proliferation of rat CD4+ T cell and modulates suppressive activity mediated by CD4+ CD25+ T cell. Int Immunol 2007; 19: 193-201.
4. Li J, Song W, Czerwinski DK, Varghese B, Uematsu S, Akira S et al. Lymphoma Immunotherapy with CpG oligodeoxynucleotides Requires TLR9 Either in the Host or in the Tumor Itself. J Immunol 2007; 179 2493-2500.
5. Duramad O, Fearon KL, Chang B, Chan JH, Gregorio J, Coffman RL et al Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation. J. Immunol 2005; 174: 5193-5200.
6. Latz E, Verma A, Visintin A, Gong M, Sirois CM, Klein DCG et al. Ligand-induced conformational changes allosterically activate Toll-like receptor 9. Nat Immunol 2007; 8: 772-779.
7. Ashman RF, Goeken, JA, Drahos J, Lenert P. Sequence requirements for oligodeoxyribonucleotide inhibitory activity. Int Immunol 2005; 17: 411-420.
8. Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 2008; 27: 161-167.
9. Lin M-T, Storer B, Martin PJ, Tseng L-H, Gooley T, Chen P-J et al. Relation of an interleukin-10 promotor polymorphism to graft-versus-host disease and survival after hematopoietic cell transplantation. N Engl J Med 2003; 349: 2201-2210.
10. Elmaagacli AH, Koldehoff M, Hindahl H, Trenschel R, Peceny R, Ottinger H et al. Mutations in innate immune system NOD2/CARD 15 and TLR-4 (Thr399Ile) genes influence the risk for severe acute GVHD in patients who underwent an allogeneic transplantation. Transplantation 2006; 81: 247-254.
11. Elmaagacli AH, Koldehoff M, Steckel NK, Trenschel R, Ottinger H, Beelen DW. Cytochrome P450 2C19 loss-of-function polymorphism is associated with an increased treatment-related mortality in patients undergoing allogeneic transplantation. Bone Marrow Transplant 2007; 40: 659-664.
12. Elmaagacli AH, Koldehoff M, Landt O, Beelen DW. Relation of an Interleukin-23 Receptor gene polymorphism to Graft-versus-Host Disease after Hematopoietic-Cell Transplantation. Bone Marrow Transplant 2008; 41: 821-826.
13. Tao K, Fujii M, Tsukumo S-I, Maekawa Y, Kishihara K, Kimoto Y et al Genetic variations of Toll-like receptor 9 predispose to systemic lupus erythematosus in Japanese population. Ann Rheum Dis 2007; 66: 905-909.
14. Berghöfer B, Frommer T, König IR, Ziegler A, Chakrabortyz T, Bein G et al. Common human Toll-like receptor 9 polymorphisms and haplotypes: Association with atopy and functional relevance. Clin Exp Allergy 2005; 35: 1147-1154.
15. Novak N, Yu C-F, Bussmann C, Maintz L, Peng W-M, Hart J et al. Putative association of a TLR9 promoter polymorphism with atopic eczema. Allergy 2007; 62: 766-772.
16. Ottinger HD, Ferencik S, Beelen DW, Lindemann M, Peceny R, Elmaagacli AH et al. Hematopoietic stem cell transplantation: Contrasting the outcome of transplantations from HLA-identical siblings, partially HLA-mismatched unrelated donors. Blood 2003; 102: 1131.
17. Elmaagacli AH, Basoglu S, Peceny R, Trenschel R, Ottinger H, Lollert A et al. Improved disease-free-survival after transplantation of peripheral blood stem cells as compared to bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia. Blood 2002; 99: 1130-1135.
18. Maniatis T, Fritsch EF, Sambrook J. Molecular Cloning. A Laboratory Manual. Cold Spring Harbor Laboratory Press, 1982.
19. Hamann L, Hamprecht A, Gomma A, Schumann RR. Rapid and inexpensive real-time PCR for genotyping functional polymorphisms within the Toll-like receptor-2, -4, -9 genes. J Immunol Methods 2004; 285 281-291.
20. Elmaagacli AH, Freist A, Hahn M, Opalka B, Seeber S, Schaefer UW et al. Estimating the relapse stage in chronic myeloid leukaemia patients after allogeneic stem cell transplantation by the amount of bcr-abl fusion transcripts detected using a new real-time polymerase chain reaction method. B J Haemtol 2001; 113: 1072-1075.
21. Steckel N, Koldehoff M, Ditschkowski M, Beelen DW, Elmaagacli AH. Use of the activating gene mutation of the tyrosine kinase (VAL617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis with myeloid metaplasia after allogeneic stem cell transplantation. Transplantation 2007; 83: 1518-1520.
22. Satoh, Akatsu T, Ishikawa Y, Minami Y, Takahashi Y, Nakamura M. Association between toll-like receptor 8 expression and adverse clinical outcomes in patients with enterovirus-associated dilated cardiomyopathy. Am Heart J 2007; 154: 581-588.
23. Ottinger HD, Beelen DW, Scheulen B, Schaefer UW, Grosse-Wilde H. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 1996; 88: 2775-2779.
24. Prezpiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus conference on acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
25. Sullivan KM, Agura E, Anasetti C, Appelbaum D, Badger C, Barman S et al. Chronic graft-versus-host-disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250-259.
26. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
27. Cox DR. Regression models and life-tables. J R Stat Soc 1972; 34: 187.
28. Calcaterra C, Sfondrini L, Rossigni A, Sommaria M, Rumio C, Me'nard S, Balsari A. Critical Role of TLR9 in Acute Graft-versus-Host Disease. J of Immunol 2008; 181: 6132-6139.
29. Einsele H, Ehninger G, Steidle M, Fischer I, Bihler S, Gerneth F et al. Lymphocytopenia as an unfavorable prognostic factor in patients with cytomegalovirus infection after bone marrow transplantation. Blood 1993; 82: 1672-1678.
30. Blazar BR, Krieg AM, Taylor PA. Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients. Blood 2001; 98: 1217-1225.
31. Jiang W, Lederman MM, Harding CV, Rodriguez B, Mohner RJ, Sieg SF. TLR9 stimulation drives naive B cells to proliferate and to attain enhanced antigen presenting function. Eur J Immunol 2007; 37: 2205-2213.